Search

Displaying results 3081 - 3090 of 10000 in total
  1. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  2. Drug

    Tibolone

    go.drugbank.com/drugs/DB09070
    ApprovedInvestigational

    Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the development of osteoporosis [L1876]. … Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874].

    Synonyms: 17-hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one
  3. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism

  4. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.

  5. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

  6. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. … It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  7. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    [L4168] It was approved for the same indications in Canada in June 2022. … Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.[A36741]

  8. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    [A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … [A259606] Estrogen is a potent neuromodulator, particularly in the hypothalamus, and has been shown to be involved as a negative regulator in generating Gonadotropin-releasing hormone (GnRH) pulse through

  9. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. … [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.[L7901]

  10. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. … Bufexamac was also withdrawn by the EMA in April 2010.

    Synonyms: 4-Butoxy-N-hydroxybenzeneacetamide